Xeris to Launch Stable Glucagon in H2 ’19

In Xeris’s Q3 ’18 10-Q SEC filing, the company disclosed plans to launch its stable glucagon pen for hypoglycemia rescue in H2 ’19, which is later than previously projected by FENIX. Recall, Xeris recently stated that the FDA PDUFA date is on June 10, 2019. Below, FENIX explores potential reasons for the later-than-anticipated launch as well as key exhibition opportunities for Xeris.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.